je.st
news
Pfizer Receives U.S. FDA Accelerated Approval Of IBRANCE (palbociclib)
2015-02-04 06:14:13| drugdiscoveryonline Home Page
Pfizer Inc. recently announced the U.S. Food and Drug Administration (FDA) has granted accelerated approval of IBRANCE (palbociclib), in combination with letrozole, for the treatment of postmenopausal women with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced breast cancer as initial endocrine-based therapy for their metastatic disease
Tags: approval
receives
accelerated
fda
Category:Biotechnology and Pharmaceuticals